An Indian Post Marketing Study of Mealtime Insulin, Fiasp®, to Evaluate Its Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice

Novo Nordisk A/S42 enrolled

Overview

This study is to investigate the effects of Fiasp®, a mealtime insulin, in patients with diabetes mellitus. The purpose of this study is to collect information about Fiasp®, which is prescribed to the participants by their doctors. Participants will administer Fiasp® as prescribed by their doctors. The study will last for about 6 months.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2

Interventions

Faster-acting insulin aspartDRUG

Faster-acting insulin aspart given as subcutaneous (s.c., under the skin) injections according to routine clinical practice. The decision to initiate treatment with commercially available Fiasp® must be made by the patient and the treating physician before and independently from the decision to include the patient in this study.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. * Male or female, age equal to or above 18 years at the time of signing the informed consent. * Patients diagnosed with diabetes mellitus. * Patients scheduled to start treatment with Fiasp® based on the clinical judgement of their treating physician. Exclusion Criteria: * Known or suspected hypersensitivity to study product(s) or related products. * Patients on or likely to use insulin pump therapy during the study period * Previous participation in this study. Participation is defined as having given signed informed consent. * Mental incapacity, unwillingness or language barriers hindering adequate understanding or cooperation. * Participation in any clinical study of an approved or non-approved investigational medicinal product within 1 month before treatment start. * Any disorder which in the opinion of the treating physician may jeopardise the patient's safety or compliance with the protocol.

Locations (36)